|
1
|
Moniri MR, Dai LJ and Warnock GL: The
challenge of pancreatic cancer therapy and novel treatment strategy
using engineered mesenchymal stem cells. Cancer Gene Ther.
21:12–23. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vincent A, Herman J, Schulick R, Hruban RH
and Goggins M: Pancreatic cancer. Lancet. 378:607–620. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Michaud DS: Epidemiology of pancreatic
cancer. Minerva Chir. 59:99–111. 2004.PubMed/NCBI
|
|
4
|
Tamburrino A, Piro G, Carbone C, Tortora G
and Melisi D: Mechanisms of resistance to chemotherapeutic and
anti-angiogenic drugs as novel targets for pancreatic cancer
therapy. Front Pharmacol. 4:562013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hingorani SR, Petricoin EF, Maitra A,
Rajapakse V, King C, Jacobetz MA, Ross S, Conrads TP, Veenstra TD,
Hitt BA, et al: Preinvasive and invasive ductal pancreatic cancer
and its early detection in the mouse. Cancer Cell. 4:437–450. 2003.
View Article : Google Scholar
|
|
6
|
Burris HA 3rd, Moore MJ, Andersen J, Green
MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo
AM, Tarassoff P, et al: Improvements in survival and clinical
benefit with gemcitabine as first-line therapy for patients with
advanced pancreas cancer: A randomized trial. J Clin Oncol.
15:2403–2413. 1997.PubMed/NCBI
|
|
7
|
Cheng H1, Shi S, Cai X, Long J, Xu J, Liu
C and Yu X: microRNA signature for human pancreatic cancer invasion
and metastasis. Exp Ther Med. 4:181–187. 2012.PubMed/NCBI
|
|
8
|
Longati P, Jia X, Eimer J, Wagman A, Witt
MR, Rehnmark S, Verbeke C, Toftgård R, Löhr M and Heuchel RL: 3D
pancreatic carcinoma spheroids induce a matrix-rich, chemoresistant
phenotype offering a better model for drug testing. BMC Cancer.
13:952013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Qazi AM1, Gruzdyn O, Semaan A, Seward S,
Chamala S, Dhulipala V, Sethi S, Ali-Fehmi R, Philip PA, Bouwman
DL, et al: Restoration of E-cadherin expression in pancreatic
ductal adenocarcinoma treated with microRNA-101. Surgery.
152:704–711; discussion 711–713. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Borja-Cacho D, Jensen EH, Saluja AK,
Buchsbaum DJ and Vickers SM: Molecular targeted therapies for
pancreatic cancer. Am J Surg. 196:430–441. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dai ZJ, Gao J, Kang HF, Ma YG, Ma XB, Lu
WF, Lin S, Ma HB, Wang XJ and Wu WY: Targeted inhibition of
mammalian target of rapamycin (mTOR) enhances radiosensitivity in
pancreatic carcinoma cells. Drug Des Devel Ther. 7:149–159. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Papaconstantinou IG, Lykoudis PM, Gazouli
M, Manta A, Polymeneas G and Voros D: A review on the role of
microRNA in biology, diagnosis, and treatment of pancreatic
adenocarcinoma. Pancreas. 41:671–677. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xu C, Ping Y and Li X, Zhao H, Wang L, Fan
H, Xiao Y and Li X: Prioritizing candidate disease miRNAs by
integrating phenotype associations of multiple diseases with
matched miRNA and mRNA expression profiles. Mol Biosyst.
10:2800–2809. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Qiu C, Chen G and Cui Q: Towards the
understanding of microRNA and environmental factor interactions and
their relationships to human diseases. Sci Rep. 2:3182012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Weber JA, Baxter DH, Zhang S, Huang DY,
Huang KH, Lee MJ, Galas DJ and Wang K: The microRNA spectrum in 12
body fluids. Clin Chem. 56:1733–1741. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Humeau M, Torrisani J and Cordelier P:
miRNA in clinical practice: Pancreatic cancer. Clin Biochem.
46:933–936. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vlastos G and Verkooijen HM: Minimally
invasive approaches for diagnosis and treatment of early-stage
breast cancer. Oncologist. 12:1–10. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sicard F, Gayral M, Lulka H, Buscail L and
Cordelier P: Targeting miR-21 for the therapy of pancreatic cancer.
Mol Ther. 21:986–994. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cai B, An Y, Lv N, Chen J, Tu M, Sun J, Wu
P, Wei J, Jiang K and Miao Y: miRNA-181b increases the sensitivity
of pancreatic ductal adenocarcinoma cells to gemcitabine in vitro
and in nude mice by targeting BCL-2. Oncol Rep. 29:1769–1776.
2013.PubMed/NCBI
|
|
20
|
Kawaguchi T, Komatsu S, Ichikawa D,
Morimura R, Tsujiura M, Konishi H, Takeshita H, Nagata H, Arita T,
Hirajima S, et al: Clinical impact of circulating miR-221 in plasma
of patients with pancreatic cancer. Br J Cancer. 108:361–369. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang WS, Liu LX, Li GP, Chen Y, Li CY, Jin
DY and Wang XL: Combined serum CA19-9 and miR-27a-3p in peripheral
blood mononuclear cells to diagnose pancreatic cancer. Cancer Prev
Res (Phila). 6:331–338. 2013. View Article : Google Scholar
|
|
22
|
Huang J, Egger M, Grizzle W and McNally L:
MicroRNA-100 regulates IGF1-receptor expression in metastatic
pancreatic cancer cells. Biotech Histochem. 88:397–402. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gallardo E, Navarro A, Viñolas N, Marrades
RM, Diaz T, Gel B, Quera A, Bandres E, Garcia-Foncillas J and
Ramirez J: miR-34a as a prognostic marker of relapse in surgically
resected non-small-cell lung cancer. Carcinogenesis. 30:1903–1909.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang P, Chen L, Zhang J, Chen H, Fan J,
Wang K, Luo J, Chen Z, Meng Z and Liu L: Methylation-mediated
silencing of the miR-124 genes facilitates pancreatic cancer
progression and metastasis by targeting Rac1. Oncogene. 33:514–524.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhao WG, Yu SN, Lu ZH, Ma YH, Gu YM and
Chen J: The miR-217 microRNA functions as a potential tumor
suppressor in pancreatic ductal adenocarcinoma by targeting KRAS.
Carcinogenesis. 31:1726–1733. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Delpu Y, Lulka H, Sicard F, Saint-Laurent
N, Lopez F, Hanoun N, Buscail L, Cordelier P and Torrisani J: The
rescue of miR-148a expression in pancreatic cancer: An
inappropriate therapeutic tool. PLoS One. 8:e555132013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Druz A, Chen YC, Guha R, Betenbaugh M,
Martin SE and Shiloach J: Large-scale screening identifies a novel
microRNA, miR-15a-3p, which induces apoptosis in human cancer cell
lines. RNA Biol. 10:287–300. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hou B, Jian Z, Chen S, Ou Y, Li S and Ou
J: Expression of miR-216a in pancreatic cancer and its clinical
significance. Nan Fang Yi Ke Da Xue Xue Bao. 32:1628–1631.
2012.PubMed/NCBI
|
|
29
|
Jiao LR, Frampton AE, Jacob J, Pellegrino
L, Krell J, Giamas G, Tsim N, Vlavianos P, Cohen P, Ahmad R, et al:
MicroRNAs targeting oncogenes are down-regulated in pancreatic
malignant transformation from benign tumors. PLoS One.
7:e320682012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Drakaki A and Iliopoulos D: MicroRNA-gene
signaling pathways in pancreatic cancer. Biomed J. 36:200–208.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang J and Sen S: MicroRNA functional
network in pancreatic cancer: From biology to biomarkers of
disease. J Biosci. 36:481–491. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner
MR, Frankel WL, Morgan DL, Postier RG, Brackett DJ and Schmittgen
TD: Expression profiling identifies microRNA signature in
pancreatic cancer. Int J Cancer. 120:1046–1054. 2007. View Article : Google Scholar
|
|
33
|
Bloomston M, Frankel WL, Petrocca F,
Volinia S, Alder H, Hagan JP, Liu CG, Bhatt D, Taccioli C, Croce
CM, et al: MicroRNA expression patterns to differentiate pancreatic
adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA.
297:1901–1908. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhang Y, Li M, Wang H, Fisher WE, Lin PH,
Yao Q and Chen C: Profiling of 95 microRNAs in pancreatic cancer
cell lines and surgical specimens by real-time PCR analysis. World
J Surg. 33:698–709. 2009. View Article : Google Scholar
|
|
35
|
Mees ST, Mardin WA, Wendel C, Baeumer N,
Willscher E, Senninger N, Schleicher C, Colombo-Benkmann M and
Haier J: EP300 - a miRNA-regulated metastasis suppressor gene in
ductal adenocarcinomas of the pancreas. Int J Cancer. 126:114–124.
2010. View Article : Google Scholar
|
|
36
|
Szafranska AE1, Davison TS, John J, Cannon
T, Sipos B, Maghnouj A, Labourier E and Hahn SA: MicroRNA
expression alterations are linked to tumorigenesis and
non-neoplastic processes in pancreatic ductal adenocarcinoma.
Oncogene. 26:4442–4452. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Szafranska AE1, Doleshal M, Edmunds HS,
Gordon S, Luttges J, Munding JB, Barth RJ Jr, Gutmann EJ,
Suriawinata AA, Marc Pipas J, Tannapfel A, et al: Analysis of
microRNAs in pancreatic fine-needle aspirates can classify benign
and malignant tissues. Clin Chem. 54:1716–1724. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhang S, Cai X, Huang F, Zhong W and Yu Z:
Effect of trichostatin a on viability and microRNA expression in
human pancreatic cancer cell line BxPC-3. Exp Oncol. 30:265–268.
2008.PubMed/NCBI
|
|
39
|
Gironella M1, Seux M, Xie MJ, Cano C,
Tomasini R, Gommeaux J, Garcia S, Nowak J, Yeung ML, Jeang KT, et
al: Tumor protein 53-induced nuclear protein 1 expression is
repressed by miR-155, and its restoration inhibits pancreatic tumor
development. Proc Natl Acad Sci USA. 104:16170–16175. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Pawa N, Arulampalam T and Norton JD:
Screening for colorectal cancer: Established and emerging
modalities. Nat Rev Gastroenterol Hepatol. 8:711–722. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lee KJ, Yi SW, Chung MJ, Park SW, Song SY,
Chung JB and Park JY: Serum CA 19-9 and CEA levels as a prognostic
factor in pancreatic adenocarcinoma. Yonsei Med J. 54:643–649.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Liu J, Gao J, Du Y, Li Z, Ren Y, Gu J,
Wang X, Gong Y, Wang W and Kong X: Combination of plasma microRNAs
with serum CA19-9 for early detection of pancreatic cancer. Int J
Cancer. 131:683–691. 2012. View Article : Google Scholar
|
|
43
|
Wang J, Chen J, Chang P, LeBlanc A, Li D,
Abbruzzesse JL, Frazier ML, Killary AM and Sen S: MicroRNAs in
plasma of pancreatic ductal adenocarcinoma patients as novel
blood-based biomarkers of disease. Cancer Prev Res (Phila).
2:807–813. 2009. View Article : Google Scholar
|
|
44
|
Ryu JK, Hong SM, Karikari CA, Hruban RH,
Goggins MG and Maitra A: Aberrant MicroRNA-155 expression is an
early event in the multistep progression of pancreatic
adenocarcinoma. Pancreatology. 10:66–73. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Park JY, Helm J, Coppola D, Kim D, Malafa
M and Kim SJ: MicroRNAs in pancreatic ductal adenocarcinoma. World
J Gastroenterol. 17:817–827. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Morimura R, Komatsu S, Ichikawa D,
Takeshita H, Tsujiura M, Nagata H, Konishi H, Shiozaki A, Ikoma H,
Okamoto K, et al: Novel diagnostic value of circulating miR-18a in
plasma of patients with pancreatic cancer. Br J Cancer.
105:1733–1740. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Keklikoglou I, Hosaka K, Bender C, Bott A,
Koerner C, Mitra D, Will R, Woerner A, Muenstermann E, Wilhelm H,
et al: MicroRNA-206 functions as a pleiotropic modulator of cell
proliferation, invasion and lymphangiogenesis in pancreatic
adenocarcinoma by targeting ANXA2 and KRAS genes. Oncogene. Dec
15–2014, http://dx.doi.org/10.1038/onc.2014.408.
|
|
48
|
Song S and Ajani JA: The role of microRNAs
in cancers of the upper gastrointestinal tract. Nat Rev
Gastroenterol Hepatol. 10:109–118. 2013. View Article : Google Scholar
|
|
49
|
Pramanik D, Campbell NR, Karikari C,
Chivukula R, Kent OA, Mendell JT and Maitra A: Restitution of tumor
suppressor microRNAs using a systemic nanovector inhibits
pancreatic cancer growth in mice. Mol Cancer Ther. 10:1470–1480.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Pramanik D, Campbell NR, Karikari C,
Chivukula R, Kent OA, Mendell JT and Maitra A: Putative tumor
suppressor gene SEL1L was downregulated by aberrantly upregulated
hsa-mir-155 in human pancreatic ductal adenocarcinoma. Mol
Carcinog. 53:711–712. 2013.
|
|
51
|
Liu C, Cheng H, Shi S, Cui X, Yang J, Chen
L, Cen P, Cai X, Lu Y, Wu C, et al: MicroRNA-34b inhibits
pancreatic cancer metastasis through repressing Smad3. Curr Mol
Med. 13:467–478. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
MacKenzie TN, Mujumdar N, Banerjee S,
Sangwan V, Sarver A, Vickers S, Subramanian S and Saluja AK:
Triptolide induces the expression of miR-142-3p: A negative
regulator of heat shock protein 70 and pancreatic cancer cell
proliferation. Mol Cancer Ther. 12:1266–1275. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Sun T, Kong X, Du Y and Li Z: Aberrant
MicroRNAs in pancreatic cancer: Researches and clinical
implications. Gastroenterol Res Pract. 2014:3865612014. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Di Leva G and Croce CM: miRNA profiling of
cancer. Curr Opin Genet Dev. 23:3–11. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Kong X, Du Y, Wang G, Gao J, Gong Y, Li L,
Zhang Z, Zhu J, Jing Q, Qin Y and Li Z: Detection of differentially
expressed microRNAs in serum of pancreatic ductal adenocarcinoma
patients: miR-196a could be a potential marker for poor prognosis.
Dig Dis Sci. 56:602–609. 2011. View Article : Google Scholar
|
|
56
|
Frampton AE, Krell J, Jacob J, Stebbing J,
Jiao LR and Castellano L: microRNAs as markers of survival and
chemo-resistance in pancreatic ductal adenocarcinoma. Expert Rev
Anticancer Ther. 11:1837–42. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Mardin WA and Mees ST: MicroRNAs: Novel
diagnostic and therapeutic tools for pancreatic ductal
adenocarcinoma? Ann Surg Oncol. 16:3183–9. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Papaconstantinou IG, Manta A, Gazouli M,
Lyberopoulou A, Lykoudis PM, Polymeneas G and Voros D: Expression
of microRNAs in patients with pancreatic cancer and its prognostic
significance. Pancreas. 42:67–71. 2013. View Article : Google Scholar
|
|
59
|
Schultz NA, Andersen KK, Roslind A,
Willenbrock H, Wojdemann M and Johansen JS: Prognostic microRNAs in
cancer tissue from patients operated for pancreatic cancer--five
microRNAs in a prognostic index. World J Surg. 36:2699–2707. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Giovannetti E, Funel N, Peters GJ, Del
Chiaro M, Erozenci LA, Vasile E, Leon LG, Pollina LE, Groen A,
Falcone A, et al: MicroRNA-21 in pancreatic cancer: Correlation
with clinical outcome and pharmacologic aspects underlying its role
in the modulation of gemcitabine activity. Cancer Res.
70:4528–4538. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Bauer AS, Keller A, Costello E, Greenhalf
W, Bier M, Borries A, Beier M, Neoptolemos J, Büchler M, Werner J,
et al: Diagnosis of pancreatic ductal adenocarcinoma and chronic
pancreatitis by measurement of microRNA abundance in blood and
tissue. PLoS One. 7:e341512012. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Costello E, Greenhalf W and Neoptolemos
JP: New biomarkers and targets in pancreatic cancer and their
application to treatment. Nat Rev Gastroenterol Hepatol. 9:435–444.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Giovannetti E1, van der Velde A, Funel N,
Vasile E, Perrone V, Leon LG, De Lio N, Avan A, Caponi S, Pollina
LE, et al: High-throughput microRNA (miRNAs) arrays unravel the
prognostic role of MiR-211 in pancreatic cancer. PLoS One.
7:e491452012. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Preis M, Gardner TB, Gordon SR, Pipas JM,
Mackenzie TA, Klein EE, Longnecker DS, Gutmann EJ, Sempere LF and
Korc M: MicroRNA-10b expression correlates with response to
neoadjuvant therapy and survival in pancreatic ductal
adenocarcinoma. Clin Cancer Res. 17:5812–5821. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Ali S, Ahmad A, Banerjee S, Padhye S,
Dominiak K, Schaffert JM, Wang Z, Philip PA and Sarkar FH:
Gemcitabine sensitivity can be induced in pancreatic cancer cells
through modulation of miR-200 and miR-21 expression by curcumin or
its analogue CDF. Cancer Res. 70:3606–3617. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Yu J1, Ohuchida K, Mizumoto K, Sato N,
Kayashima T, Fujita H, Nakata K and Tanaka M: MicroRNA,
hsa-miR-200c, is an independent prognostic factor in pancreatic
cancer and its upregulation inhibits pancreatic cancer invasion but
increases cell proliferation. Mol Cancer. 9:1692010. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Ohuchida K, Mizumoto K, Kayashima T,
Fujita H, Moriyama T, Ohtsuka T, Ueda J, Nagai E, Hashizume M and
Tanaka M: MicroRNA expression as a predictive marker for
gemcitabine response after surgical resection of pancreatic cancer.
Ann Surg Oncol. 18:2381–2387. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Greither T, Grochola LF, Udelnow A,
Lautenschlager C, Wurl P and Taubert H: Elevated expression of
microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated
with poorer survival. Int J Cancer. 126:73–80. 2010. View Article : Google Scholar
|
|
69
|
Hasegawa S, Eguchi H, Nagano H, Konno M,
Tomimaru Y, Wada H, Hama N, Kawamoto K, Kobayashi S, Nishida N, et
al: MicroRNA-1246 expression associated with CCNG2-mediated
chemoresistance and stemness in pancreatic cancer. Br J Cancer.
111:1572–1580. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Paik WH, Kim HR, Park JK, Song BJ, Lee SH
and Hwang JH: Chemosensitivity induced by down-regulation of
microRNA-21 in gemcitabine-resistant pancreatic cancer cells by
indole-3-carbinol. Anticancer Res. 33:1473–1481. 2013.PubMed/NCBI
|
|
71
|
Bitarte N, Bandres E, Boni V, Zarate R,
Rodriguez J, Gonzalez-Huarriz M, Lopez I, Javier Sola J, Alonso MM,
Fortes P and Garcia-Foncillas J: MicroRNA-451 is involved in the
self-renewal, tumorigenicity, and chemoresistance of colorectal
cancer stem cells. Stem Cells. 29:1661–1671. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Tan L, Sui X, Deng H and Ding M: Holoclone
forming cells from pancreatic cancer cells enrich tumor initiating
cells and represent a novel model for study of cancer stem cells.
PLoS One. 6:e233832011. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Mazur PK and Siveke JT: Genetically
engineered mouse models of pancreatic cancer: Unravelling tumour
biology and progressing translational oncology. Gut. 61:1488–1500.
2012. View Article : Google Scholar
|
|
74
|
Choi SY, Lin D, Gout PW, Collins CC, Xu Y
and Wang Y: Lessons from patient-derived xenografts for better in
vitro modeling of human cancer. Adv Drug Deliv Rev. 79–80. 222–237.
2014.
|
|
75
|
Mazur PK, Herner A, Neff F and Siveke JT:
Current methods in mouse models of pancreatic cancer. Methods Mol
Biol. 1267:185–215. 2015. View Article : Google Scholar : PubMed/NCBI
|
